Metanoia Press · In preparation · Synthetic
Metanoia's focus is the natural psychedelics, but the family cannot be understood without LSD. It was the molecule that opened the modern era, shaped a culture, was banned, and, in 2026, returned to serious clinical research with some of the strongest data the field has produced. Our forthcoming book tells that full arc: the accidental discovery, the science, the fall, and the remarkable comeback.
What the Book Will Cover
Albert Hofmann, ergot, and the accidental first dose, how a Swiss chemistry program produced the most famous psychedelic on earth.
Extraordinary potency at microgram doses, a long duration, and its grip on the 5-HT2A receptor, plus why it lasts so long.
Early psychiatric promise, cultural explosion, and Schedule I, the decades the science went dark.
Pharmaceutical LSD back in Phase 3 trials, for depression and for anxiety, with striking results.
LSD was first synthesized by Albert Hofmann in 1938 and its effects discovered in 1943. It is astonishingly potent, active at millionths of a gram, and works, like the natural tryptamines, primarily through the 5-HT2A serotonin receptor, with an unusually long grip that helps explain its many-hour duration. After decades in prohibition, its clinical chapter reopened dramatically: in 2026, pharmaceutical LSD formulations advanced through late-stage trials, with one program reporting one of the largest antidepressant effect sizes on record and another receiving breakthrough designation for generalized anxiety.
Reliability: pharmacology and history are well established (strong). The 2026 clinical results are late-stage but await full peer-reviewed publication and independent replication. Full sources will accompany the finished book.
Read the published book See the latest field news See the whole family